ES2246915T3 - Composiciones para el tratamiento de anormalidades en filtraciones glomoleculares, de persistencia de canal arterial y de osteoporosis. - Google Patents

Composiciones para el tratamiento de anormalidades en filtraciones glomoleculares, de persistencia de canal arterial y de osteoporosis.

Info

Publication number
ES2246915T3
ES2246915T3 ES00984691T ES00984691T ES2246915T3 ES 2246915 T3 ES2246915 T3 ES 2246915T3 ES 00984691 T ES00984691 T ES 00984691T ES 00984691 T ES00984691 T ES 00984691T ES 2246915 T3 ES2246915 T3 ES 2246915T3
Authority
ES
Spain
Prior art keywords
group
peptide
leu
baselineskip
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00984691T
Other languages
English (en)
Spanish (es)
Inventor
Krishna G. Peri
Sylvain Chemtob
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre Hospitalier Universitaire Saint Justine
Original Assignee
Centre Hospitalier Universitaire Saint Justine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Hospitalier Universitaire Saint Justine filed Critical Centre Hospitalier Universitaire Saint Justine
Application granted granted Critical
Publication of ES2246915T3 publication Critical patent/ES2246915T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Water Treatment By Sorption (AREA)
  • Water Treatment By Electricity Or Magnetism (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pipe Accessories (AREA)
  • Flanged Joints, Insulating Joints, And Other Joints (AREA)
ES00984691T 1999-12-06 2000-12-06 Composiciones para el tratamiento de anormalidades en filtraciones glomoleculares, de persistencia de canal arterial y de osteoporosis. Expired - Lifetime ES2246915T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45548399A 1999-12-06 1999-12-06
US455483 1999-12-06

Publications (1)

Publication Number Publication Date
ES2246915T3 true ES2246915T3 (es) 2006-03-01

Family

ID=23808998

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00984691T Expired - Lifetime ES2246915T3 (es) 1999-12-06 2000-12-06 Composiciones para el tratamiento de anormalidades en filtraciones glomoleculares, de persistencia de canal arterial y de osteoporosis.

Country Status (12)

Country Link
US (1) US7442763B2 (https=)
EP (1) EP1244693B1 (https=)
JP (1) JP2003516417A (https=)
AT (1) ATE298346T1 (https=)
AU (1) AU784630B2 (https=)
CA (1) CA2396739A1 (https=)
DE (1) DE60020997T2 (https=)
ES (1) ES2246915T3 (https=)
MX (1) MXPA02005626A (https=)
NZ (1) NZ520762A (https=)
WO (1) WO2001042281A1 (https=)
ZA (1) ZA200205795B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235749A1 (en) * 1999-09-15 2004-11-25 Sylvain Chemtob G-protein coupled receptor antagonists
MXPA02005626A (es) 1999-12-06 2004-09-10 Pital Sainte Justine H Composiciones para el tratamiento de filtracion glomerular, conductos arteriosos y osteoporosis del paciente.
EP1467738A1 (en) * 2001-10-08 2004-10-20 Medical Research Council Use of prostaglandin e synthase inhibitors, or ep2 or ep4 receptor antagonists, in the treatment of a pathological condition of the uterus
JP2005511562A (ja) * 2001-10-31 2005-04-28 メディカル リサーチ カウンシル 月経困難症及び月経過多の治療のためのプロスタグランジンレセプターｅｐ２及び／又はｅｐ４のアンタゴニスト
CN1662551A (zh) * 2002-05-23 2005-08-31 瑟瑞技术公司 前列腺素e2受体亚型ep4的拮抗肽
EP1878741A3 (en) * 2002-05-23 2008-02-20 Theratechnologies Inc. Antagonistic peptides of prostaglandin E2 receptor subtype EP4
US7414029B2 (en) 2002-05-23 2008-08-19 Theratechnologies, Inc. Antagonistic peptides of prostaglandin E2 receptor subtype EP4
WO2004073589A2 (en) * 2003-02-24 2004-09-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep4 (prostaglandin e2 ep4)
US8618054B2 (en) * 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
US20150126573A1 (en) 2012-05-09 2015-05-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease
BR112023018676A2 (pt) 2021-03-18 2023-10-10 Seagen Inc Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019120D0 (en) * 1990-09-01 1990-10-17 Beecham Group Plc Novel compounds
US5508384A (en) * 1992-09-10 1996-04-16 New York University Polypeptide derived from a popamine receptor, and compositions and methods thereof
BR9406652A (pt) * 1993-03-05 1996-09-10 Cytel Corp Composição
US5869281A (en) 1993-06-25 1999-02-09 Merck Frosst Canada Inc. DNA encoding prostaglandin receptor FP
US5605814A (en) * 1993-08-31 1997-02-25 Merck Frosst Canada Inc. DNA encoding human prostaglandin receptor EP2
JPH09504174A (ja) * 1993-10-29 1997-04-28 インサイト ファーマシューティカルズ，インク． プロテアーゼネキシン１変異体を含むキメラ蛋白
EP0756604A1 (en) * 1994-04-22 1997-02-05 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Melanoma antigens
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
WO1996006856A1 (en) * 1994-08-31 1996-03-07 Robert Webber Dopamine receptor peptides and anti-peptide antibodies
WO1996019233A2 (en) * 1994-12-12 1996-06-27 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm
JPH11514207A (ja) 1995-01-25 1999-12-07 シーオーアール・セラピューティックス・インコーポレーテッド 組換えｃ１４０リセプター、そのアゴニストおよびアンタゴニスト、並びに該リセプターをコードする核酸
US5877155A (en) * 1995-03-17 1999-03-02 The Research Foundation Of State University Of New York Mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX
US6117839A (en) * 1995-06-07 2000-09-12 Gensci Regeneration Sciences, Inc. Bone stimulating factor
WO1997034621A1 (en) * 1996-03-21 1997-09-25 Cytel Corporation Hla-a2.1 binding peptides and their uses
JP2001501601A (ja) * 1996-09-12 2001-02-06 メルク エンド カンパニー インコーポレーテッド 前立腺ガンの治療において有用な共役体
US5955575A (en) * 1997-12-22 1999-09-21 Hopital Sainte-Justine Antagonists of G-protein-coupled receptor
AUPP320998A0 (en) * 1998-04-27 1998-05-21 Walter And Eliza Hall Institute Of Medical Research, The Tyrosine phosphatase IA-2 T-cell epitopes
US6984719B1 (en) * 1998-09-17 2006-01-10 Hospital Sainte-Justine Peptide antagonists of prostaglandin F2α receptor
US20040235749A1 (en) * 1999-09-15 2004-11-25 Sylvain Chemtob G-protein coupled receptor antagonists
MXPA02005626A (es) 1999-12-06 2004-09-10 Pital Sainte Justine H Composiciones para el tratamiento de filtracion glomerular, conductos arteriosos y osteoporosis del paciente.

Also Published As

Publication number Publication date
AU784630B2 (en) 2006-05-18
AU2134001A (en) 2001-06-18
EP1244693A1 (en) 2002-10-02
NZ520762A (en) 2005-02-25
US20030017988A1 (en) 2003-01-23
ATE298346T1 (de) 2005-07-15
CA2396739A1 (en) 2001-06-14
DE60020997D1 (de) 2005-07-28
EP1244693B1 (en) 2005-06-22
WO2001042281A1 (en) 2001-06-14
DE60020997T2 (de) 2006-05-24
ZA200205795B (en) 2007-01-31
JP2003516417A (ja) 2003-05-13
MXPA02005626A (es) 2004-09-10
US7442763B2 (en) 2008-10-28

Similar Documents

Publication Publication Date Title
ES2273849T3 (es) Composiciones farmaceuticas que comprenden compuestos ciclicos peptidometicos con giro beta.
JP6203215B2 (ja) プロミニン−１ペプチド断片およびその使用
ES2446292T3 (es) Tratamiento del accidente cerebrovascular y otras enfermedades sin inhibir los canales de calcio de tipo N
ES2268854T3 (es) Inhibidores de la vascularizacion.
US12162915B2 (en) Cell penetrating peptides that inhibit IRF5 nuclear localization
ES2246915T3 (es) Composiciones para el tratamiento de anormalidades en filtraciones glomoleculares, de persistencia de canal arterial y de osteoporosis.
JP2014510758A (ja) ほ乳類において脂肪細胞を標的とするための方法および組成物
JP6046493B2 (ja) プロミニン−１の血管新生促進フラグメントおよびその使用
HUE026131T2 (en) Beta-arresin effector and preparations and methods for their use
ES3057215T3 (en) Antagonist binding to dpep-1 for use in treating or preventing acute kidney injury or ischemia-reperfusion injury
US20040023853A1 (en) Antagonistic peptides of prostaglandin E2 receptor subtype EP4
JP2007506713A (ja) 例えば、抗血管新生活性を有するペプチドおよび治療におけるその適用
ES2369470T3 (es) Antagonistas de un receptor acoplado a la proteina g.
JP2003516417A5 (https=)
WO2006041205A1 (ja) 血管形成促進剤
WO2014119753A1 (ja) マイオスタチン阻害ペプチド
JP2015506960A (ja) β−アレスチンエフェクターおよび組成物ならびにそれらの使用方法
US7414029B2 (en) Antagonistic peptides of prostaglandin E2 receptor subtype EP4
US11541101B1 (en) LEMD3 antagonizes TGF-beta-driven Smad2/3 transcription in a stiffness-dependent fashion in both the nucleus and cytosol
WO2026006884A1 (en) Modulators of fxii-upar
US7976837B2 (en) Method of preventing and treating brain infarction
WO2020000063A1 (en) Rheumatoid arthritis treatment